BBP-398 (Formerly known as IACS-15509)

Phase 1Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
30
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumor, Solid

Conditions

Tumor, Solid

Trial Timeline

Nov 12, 2020 โ†’ Jul 30, 2024

About BBP-398 (Formerly known as IACS-15509)

BBP-398 (Formerly known as IACS-15509) is a phase 1 stage product being developed by BridgeBio Pharma for Tumor, Solid. The current trial status is terminated. This product is registered under clinical trial identifier NCT04528836. Target conditions include Tumor, Solid.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04528836Phase 1Terminated

Competing Products

20 competing products in Tumor, Solid

See all competitors
ProductCompanyStageHype Score
E7050EisaiPhase 1
33
FruquintinibHUTCHMEDPhase 1
28
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
CixutumumabEli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
[203Pb]VMT-ฮฑ-NET + [212Pb]VMT-ฮฑ-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-ฮฑ-NETPerspective TherapeuticsPhase 1
25
[212Pb] VMT-ฮฑ-NETPerspective TherapeuticsPhase 1
25
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
25
ZN-c3 + Bevacizumab + PembrolizumabZentalis PharmaceuticalsPhase 1
25
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
25
AzenosertibZentalis PharmaceuticalsPhase 1
25
IMC-18F1Eli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
ACR-2316Acrivon TherapeuticsPhase 1
25
agenT-797 + Approved ICIsMiNK TherapeuticsPhase 1
25